# Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers

> **NCT03522012** · PHASE1 · COMPLETED · sponsor: **Mycenax Biotech Inc.** · enrollment: 190 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT03522012
- **Lead sponsor:** Mycenax Biotech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-17
- **Primary completion:** 2018-09-26
- **Final completion:** 2018-12-20
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03522012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03522012, "Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03522012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*